GalChimia

GalChimia is a privately-held, revenue-generating service provider in the small molecule and drug delivery sectors. Its core business is offering high-end custom chemical synthesis, chiral separations, and process chemistry services to pharmaceutical and biotech companies, leveraging deep expertise in complex multi-step organic synthesis. The company demonstrates scientific credibility through peer-reviewed publications and conference participation, and has spun out a biotech venture, Iteria Biopharma, to develop its own internal programs. Its outlook is tied to the sustained demand for outsourced chemistry expertise in drug discovery and development.

Advanced synthetic organic chemistry platform specializing in complex multi-step synthesis, chiral/achiral separations, process chemistry, scale-up, and analytical services for small molecules.

GalChimia competes in the global CRDMO market against large players like Lonza, Catalent, and Evotec, as well as numerous specialized chemistry shops. Its differentiation is its deep expertise in complex, multi-step synthesis and chiral chemistry, positioning it as a high-end specialist rather than a low-cost volume provider, primarily within the European market.